



Leverage orthogonal ciEF, icIEF-UV/MS and LC-MS workflows for comprehensive biotherapeutic characterization


Greg Roman
Sr. Scientist
Biopharma Applications SCIEX

MKT-32354-A © 2024 DH Tech. Dev. Pte. Ltd.



Challenges with biotherapeutic characterization

- Sequence confirmation, charge heterogeneity assessment and post-translation modifications (PTMs) analysis are key elements of comprehensive biotherapeutic characterization to ensure the safety, efficacy and consistent quality of drug molecules
- Characterization of modern biotherapeutics with increasing diversity and complexity typically involves multiple analytical assays using different instrument platforms and software packages. This increases the investment in resources, the length of a development cycle and the difficulty of method implementation across labs
- Rapid charge heterogeneity analysis, accurate PTM localization and clear differentiation of amino acids isomers are all challenging using traditional analytical assays



SCIEX portfolio: characterization, screening and QC


ZenoTOF 7600 system



Routine to advanced
characterization

- Comprehensive characterization using electron-activated dissociation (EAD)
 - Localization of PTMs such as glycation and glycosylation
 - Differentiation of isomers such as Leu vs. Ile and Asp vs. isoAsp
 - Disulfide bond mapping
 - Middle-down analysis
 - Single-injection platform method

Intabio ZT system



Routine screening
and characterization

- Rapid charge heterogeneity analysis using icIEF-UV/MS
 - Intact N- and O-glycan distribution
 - Stability profiling
 - For example, deamidation, oxidation, glycation
 - Free thiol/cysteinylation
 - Bioconjugation and distribution


BioPhase 8800 system




High throughput &
GMP-ready

- High throughput screening and monitoring using ciEF
 - Charge variant separation and pI determination
 - Low molecular weight impurity sizing
 - Released N-glycan GU determination

A single MS platform to achieve complete characterization



ZenoTOF 7600 system







icIEF-UV/MS
Charge variants
Intact proteoform analysis

Peptide mapping
Glycoforms, PTMs
Disulfide mapping
Isomer ID

Peptide quantitation

Middle-down
Subunit sequence
Clipping and PTM analyses
Disulfide mapping



The promise of EAD for biomolecules

ELECTRON ACTIVATED DISSOCIATION (EAD)

- Data-dependent acquisition platform method for peptide mapping – no need for optimization
- Improved bottom-up characterization performance to meet the challenges of complex next gen therapeutics
 - Confirmation of PTMs (glycosylation, disulfide-bonds, phosphorylation, sulfation, ...)
 - Detailed determination of aa isomers
 - Fragmentation of singularly, doubly and multiply charged ions
 - Comprehensive sequence coverage
- Routine and reliable similar to CID MS/MS: set and forget
- Only alternative fragmentation technique with sensitivity improvements using the **Zeno trap**
- Allows for sequence information directly from the intact molecule (top/middle down)
- Wide range of electron energy adjustments (up to 25 eV) allows for high degree of selectivity for backbone fragmentation and maintenance of side chain
- Potential to support quantification

7600: Solving the sensitivity gap with the zenoTrap


ZENO TRAP

- Given the disperse nature of ion current in EAD, sensitivity enhancement is needed to operate at routine levels
- Normally ions are lost in between TOF pulses primarily due to velocity differences
 - The Zeno trap gains ion transmission back by timing the ion injection from the Zeno gate with subsequent extraction pulses
 - The Zeno trap contains critical technology to enhance MS/MS sensitivity, for both CID and EAD
 - EAD and Zeno trap are designed to work together to significantly improve data quality for alternative fragmentation

What is duty cycle?

... AND WHY IS DUTY CYCLE IMPORTANT?


- % of ions injected into the TOF
 - Typically, ~5-25%
 - Dependent on
 - Fragment mass
 - Scan range upper limit
- Ion losses occur when mating:
 - Pulsed measurement technique
 - TOF
 - Continuous ion beam
 - Quadrupole



Zeno trap


FOR SENSITIVITY GAINS IN MS/MS

- The Zeno trap provides control of the ion beam from the collision cell into the accelerator
- Ions exit the Zeno trap in an ordered release based on potential energy
 - Ions are generally released from a high m/z to low m/z
 - All ions now arrive in the accelerator at the same time and location




Enhancing sensitivity for time-of-flight MS/MS



GAIN USING THE ZENO TRAP




GAIN VS. FRAGMENT M/Z



Electron activated dissociation (EAD)





- Free electrons are captured by ions and form a radical state which then fragments
- Electrons introduced with different energies will induce fragmentation in different molecule types
- EAD cell enables you to perform ECD, Hot ECD and EIEIO in single instrument



EAD technology from SCIEX

- **Fast** fragmentation and acquisition¹⁻³
 - Electron capture reaction times of 10–30 ms
 - DDA on LC timescale up to 20 Hz
- **Reproducible** at a quantitative level
- **Reagent-free** electron capture dissociation²
- **Tunability** of electron kinetic energy (KE) from 0 eV to 25 eV¹⁻³
- **Single-injection platform method** for routine to advanced biopharma characterization



¹Takashi Baba *et al.* (2015) Electron capture dissociation in a branched radio-frequency ion trap. *Anal. Chem.* 87(1):785-792.

²Takashi Baba *et al.* (2021) Dissociation of biomolecules by an intense low-energy electron beam in a high sensitivity time-of-flight mass spectrometer. *J. Am. Soc. Mass Spectrom.* 32(8):1964-1975.

³Takashi Baba *et al.* (2022) Electron impact excitation of ions from organics on singly protonated peptides with and without post-translational modifications. *J. Am. Soc. Mass Spectrom.* 33(9):1723-1732.

Advantages of EAD for biopharma characterization

Application	CID	EAD	ExD
Single-injection platform method	√	√	×
Full sequence coverage	√	√	×
Labile modifications	×	√	√*
Isomer differentiation	×	√	√*
Di-/tri-sulfide bond mapping	√*	√	√
Long peptides (>5 kDa)	√*	√	√
Singly charged species	√	√	×
Middle-down analysis	√*	√	√*



- Accurate localization of labile modifications
- Confident differentiation of amino acid or positional isomers
- Di-/tri-sulfide bond mapping
- High sequence coverage of antibody subunits
- Fast and sensitive platform method
- Quantitatively reproducible
- Tunability of electron KE for challenging molecules

EAD provides superior comprehensive characterization of protein therapeutics as a platform method in a single injection

** Not optimal in certain cases*

EAD vs CID for glycopeptide characterization

- Complex structures of N-linked glycosylation
- Absence of a consensus sequence and the presence of positional isomers for O-linked glycosylation
- While localization of labile glycan moieties using collision-based MS/MS is challenging, EAD can provide site-specific information about glycosylation^{1,2}



¹A new electron activated dissociation (EAD) approach for comprehensive glycopeptide analysis of therapeutic proteins. SCIEX technical note, RUO-MKT-02-12980-A.





²Comprehensive characterization of O-linked glycosylation in etanercept by electron activated dissociation (EAD). SCIEX technical note, RUO-MKT-02-14921-A.

Biologics Explorer software



Intuitive workflow templates for intact, peptide mapping, and middle-down data analysis

Full toolset for automated data interpretation and results review, comparison, and visualization





Comprehensive characterization of infiximab using ciEF, icIEF-UV/MS and LC-MS workflows




Variant detection, characterization and monitoring



icIEF/UV-MS workflow achieves the same separation as cIEF and identifies the proteoforms contributing to the basic variants




Subunit mass analysis confirms the presence of abundant lysine species on Fc



Characterization



Middle-down and peptide mapping workflows identify the C-terminal lysine variant




Detection

cIEF workflow detects an abnormally high level of basic variants




Monitoring

Subunit mass analysis





Subunit mass analysis revealed the presence of abundant lysine variants on the Fc/2 subunit





Peptide mapping and middle-down analyses

Peptide
mapping




Middle
down



- Middle-down and peptide mapping and workflows provide a multi-level confirmation of the species with or without the C-terminal Lys


ADC characterization





icIEF-UV/MS workflow provides high-resolution separation and sensitive detection of charge variants for rapid screening and monitoring of intact ADCs



Intabio ZT system



Biologics
Explorer
software





Single-injection EAD based peptide mapping workflow offers high sequence coverage of ADCs for confident variant identification and accurate PTM or payload localization



ZenoTOF 7600 system
MicroLC M5 system



EAD DDA



EAD-based workflows for comprehensive characterization of biotherapeutics




Glycan localization and isomer differentiation



- EAD resulted in excellent fragmentation of the O-glycopeptide backbone and the formation of glycan-containing fragments, allowing accurate localization of the O-glycan and confident differentiation of 2 positional isomers (S vs. T glycosylated)¹

¹Comprehensive characterization of O-linked glycosylation in etanercept by electron activated dissociation (EAD). SCIEX technical note, RUO-MKT-02-14921-A.


Accurate localization of multiple O-linked glycans




- EAD provides excellent fragmentation of long glycopeptides
- High-quality EAD data led to accurate localization of glycosylation for etanercept glycopeptides carrying as many as 7 O-linked glycan moieties

Challenges with glycation characterization

Poor fragmentation by CID




Excellent fragmentation by EAD



- Glycated peptides and advanced glycation end products (AGEs) are difficult to fragment by CID
- CID leads to preferential cleavage of H₂O from the hexose moiety and low yield of sequence ions¹
- Enzymatic digestion of glycated or AGE species, in which Lys and/or Arg residues are modified, leads to the formation of many long peptides containing the glycation and/or AGE moieties, and the length of these species poses an additional challenge to CID

¹Comprehensive characterization of glycation in protein therapeutics using electron activated dissociation (EAD). SCIEX technical note, RUO-MKT-02-15020-A.

Simultaneous localization of multiple modifications




- Excellent EAD data allowed for simultaneous localization of 3 modifications, including 1 N-linked glycan (G1F) on an Asn residue, 1 AGE modification (3DG-H) on an Arg residue and 1 glycation moiety (Hex) on a Lys residue. Such depth of information cannot be achieved using CID^{1,2}

¹Comprehensive characterization of glycation in protein therapeutics using electron activated dissociation (EAD). SCIEX technical note, RUO-MKT-02-15020-A.


²Comprehensive characterization of advanced glycation end products (AGEs) in protein therapeutics using electron activated dissociation (EAD). SCIEX technical note, RUO-MKT-02-15088-A.

Differentiation of amino acid isomers using EAD

Challenges





EAD




Solution

EAD





EAD







- EAD generates diagnostic fragments for clear differentiation of amino acid isomers

Deamidation isomers in heat-stressed NISTmAb



Comprehensive differentiation of deamidation isomers from forced degradation by electron activation dissociation (EAD). SCIEX technical note, RUO-MKT-02-14730-A.


Isomer differentiation for sequence variant analysis



Xle = Leu or Ile


Differentiation of leucine and isoleucine for enhanced sequence variant analysis using electron activated dissociation. SCIEX technical note, MKT-30799-A.

Differentiation of 3- and 4-hydroxyproline



- EAD generates signature z - 27 and z - 43 fragments for 3- and 4-hydroxyproline (Hyp) isomers, respectively, for the unambiguous differentiation of these 2 Hyp isomers


Hyp species in a real-world sample



- EAD led to confident identification of a 4-Hyp species in a real-world sample due to the detection of a z - 43 fragment


Single-injection EAD-based middle-down workflow

Informative, reproducible and streamlined




**ZenoTOF 7600
system**


**Zeno
EAD**




**Biologics Explorer
software**




**High sequence coverage
(70%-90%)¹⁻⁵**



**Confident sequence and
PTM analyses¹⁻⁵**



Rapid disulfide bond mapping^{4,5}



¹Obtaining high sequence coverage and confident post-translational modification (PTM) analysis of biotherapeutics using an electron activated dissociation (EAD)-based middle-down workflow. SCIEX technical note, MKT-27223-A.


²Comparative analysis of biotherapeutics using an electron-activated dissociation (EAD)-based middle-down workflow. SCIEX technical note, MKT-27427-A.

³Confident sequence analysis of a trispecific antibody using an electron-activated dissociation (EAD)-based middle-down workflow. SCIEX technical note, MKT-27784-A.


⁴Achieving ultrahigh sequence coverage and high-confidence disulfide bond mapping of biotherapeutics using an electron-activated dissociation (EAD)-based middle-down workflow. SCIEX technical note, MKT-28565-A.

⁵An enhanced single-injection middle-down workflow to achieve high sequence coverage and disulfide mapping of antibody subunits. SCIEX technical note, MKT-30575-A.


Sequence analysis and disulfide bond mapping



High-quality middle-down data from EAD




- EAD leads to extensive fragmentation of fully reduced or disulfide-linked subunits for enhanced middle-down characterization of biotherapeutic subunits



Achieving ultrahigh sequence coverage and high-confidence disulfide bond mapping of biotherapeutics using an electron-activated dissociation (EAD)-based middle-down workflow. SCIEX technical note, MKT-28565-A.

EAD-based middle-down analysis of a trispecific antibody





TOF MS

GGGSX...GGSG
SGGGGSX...GG

2 candidate sequences
for the HC1 P1 subunit

EAD



Disulfide bond mapping

Comprehensive mapping of disulfide linkages in etanercept using an electron activated dissociation (EAD) based LC-MS/MS methodology

Featuring the ZenoTOF 7600 system and Biologics Explorer

Zhengwei Chen and Lei Xiong
SCIEX, USA




Figure 2. CID and EAD MS/MS spectra of disulfide peptide VTCTVVVDVSHEDPECK (Cys281-Cys341).

Comprehensive characterization of an antibody-drug conjugate (ADC) using electron activated dissociation (EAD)




Figure 1. The EAD-based peptide mapping workflow offered by the ZenoTOF 7600 system enables confident sequence confirmation and accurate determination of the payload conjugate sites in T-DM1. The cytotoxic payload, DM1, was retained in the EAD fragments, leading to its accurate localization in the ADC using Biologics Explorer software. MCC: maleimidomethyl cyclohexane-1-carboxylate.

Journal of Lipid Research. 59, 2018

Article

 Read Online

ACCESS | Metrics & More | Article Recommendations | Supporting Information

VTCTLFQTQPVIPQPPDGAEA *bovine*
 EAPSAPVDAAGPTPSAAGPPVAVVVGPSVVA *fetuin*
 271 298 282 290 296
 5 eV
 VPLPLHR

KEYWORDS: electron-activated dissociation, hot electron capture dissociation, mass spectrometry, O-linked glycopeptides, fetuin, time-of-flight mass spectrometer, scheduled high-resolution multiple reaction monitoring, Zeno trap pulsing

 Read Online

ACCESS | Metrics & More | Article Recommendations | Supporting Information

ACS Partner Journal

 Journal of the American Society for
Mass Spectrometry

pubs.acs.org/iasms

Article

 Read Online


[ACCESS](#) | [Metrics & More](#) | [Article Recommendations](#) | [Supporting Information](#)

KEYWORDS: electron-induced dissociation, photofragmentation, phosphorylation modifications, fragmentation method, EAD, ETD, UVPD

Isoelectric focusing electrophoresis combined to the 7600 for the analysis of ADC's




Trastuzumab emtansine (Kadcyla, T-DM1)




Lys-conjugated
Non-specific
Avg. DAR of ~3.5

Trastuzumab deruxtecan (Enhertu, T-DXd)






Cys-conjugated
Site-specific
Fixed DAR of 8

Genovis ADC




Conjugated via GlyCLICK®
(property of Genovis AB)
Site-specific
Fixed DAR of 2

icIEF-UV/MS analysis of T-DM1




The separation of charge variants is maintained after chemical mobilization.

Deconvoluted mass spectra




MKT-33166-A




- The major peaks identified were G0F and G1F glycoforms of T-DM1 carrying 2-6 payloads. A mass difference of +958 Da measured between the adjacent major peaks corresponds to the DM1 payload conjugated with the MCC linker
- Low-abundant peaks with a mass difference of +221 Da can be attributed to the ADC conjugated with 1 free linker but not the DM1 payload

Results visualization within Biologics Explorer software


Ion map



3D view




Automated DAR calculation





icIEF-UV/MS analysis of Genovis ADC


icIEF-UV



BPE






ADC




mAb

Charge variants identified by icIEF-UV/MS



Impurity assessment



- DAR1+GlcNAcFuc was measured to be ~0.5%, demonstrating the high sensitivity of icIEF-UV/MS and the high efficiency of payload conjugation using GlyCLICK

- SCIEX offers a complete analytical solution for comprehensive characterization of biotherapeutics and their charge variants using a single MS platform
- Orthogonal, streamlined cIEF, icIEF-UV/MS, EAD-based peptide mapping and middle-down workflows provide an in-depth charge heterogeneity analysis of mAbs and ADCs, allowing confidence in assignments beyond traditional workflows such as fraction collection and CID-based peptide mapping
- icIEF-UV/MS workflow provides high-resolution separation, sensitive detection and confident identification of biotherapeutic charge variants
- EAD-based peptide mapping workflow leads to excellent peptide fragmentation, high sequence coverage and accurate PTM localization in a single injection
- EAD-based middle-down workflow allows rapid sequence confirmation, PTM localization and disulfide bond mapping

Acknowledgments

- **SCIEX**
 - Haichuan Liu
 - Rashmi Madda
 - Marcia Santos
 - Scott Mack
 - Zoe Zhang
 - Maggie Ostrowski
 - Steven Calciano
 - Roxana McClosky
 - Elliott Jones
- **Janssen**
 - Hirsh Nanda
 - Andrew Mahan
- **Amgen**
 - Shuai Wu
 - John Hui
 - Iain Campuzano
- **Bioprocessing Technology Institute (BTI)**
 - Xuezhi Bi
- **Genovis**
 - Maria Ekemohn
 - John Lindsay
 - Laurent Rieux
 - Camilla Sivertsson
 - John Turman
 - Philip Widdowson



Thank you!



The SCIEX clinical diagnostic portfolio is For In Vitro Diagnostic Use. Rx Only. Product(s) not available in all countries. For information on availability, please contact your local sales representative or refer to www.sciex.com/diagnostics. All other products are For Research Use Only. Not for use in Diagnostic Procedures.

Trademarks and/or registered trademarks mentioned herein, including associated logos, are the property of AB Sciex Pte. Ltd. or their respective owners in the United States and/or certain other countries (see www.sciex.com/trademarks).

Intabio is used under license.

© 2024 DH Tech. Dev. Pte. Ltd. MKT-32354-A